Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Attendees will hear news about the second probable HIV cure, long-acting injectable meds and COVID-19.
Expanded access study confirms the long-acting monoclonal antibody works well in people with extensive prior treatment.
Which other cities have aimed for these targets, and how are they doing?
Long-acting injectables may be given once every other month, according to new findings.
Factors such as mental health and food security were associated with higher rates of successful HIV treatment among trans women.
Some groups, however, including Black and Latino men and homeless people, are not faring as well as others.
Cabotegravir plus rilpivirine maintenance therapy worked equally well when taken monthly or every two months.
Researchers compared experiences with stigma among Black women in Chicago and Birmingham.
Starting Symtuza quickly after HIV diagnosis is tied to high viral suppression.
A recent study found that factors such as mental health and food security were associated with higher rates of successful HIV treatment.
French study finds taking meds for four days with three days off is as effective as daily therapy—and costs 43% less.
Generalized anxiety disorder is associated with lower rates of HIV treatment, adherence to treatment and viral suppression.
Continuum of care review finds 80% of transgender women in care achieve an undetectable viral load.
Tests and PrEP info are available Thursday, June 27, which marks National HIV Testing Day.
A new analysis finds that Obamacare has driven down the proportion of individuals without insurance.
The CDC estimates that 40 percent of the 1.1 million people with HIV are undiagnosed or not receiving medical care for the virus.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.